JamesSpeyerMD

Oncology • New York, NY

Professor of Medicine, NYU School of Medicine

Join to view full profile

Dr. Speyer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Speyer's full profile

Already have an account?

Office
160 East 34th Street
4th Floor
New York, NY 10016
Phone+1 212-731-5432
Is this information wrong?

Education & Training

National Institutes of Health Clinical CenterFellowship, Medical Oncology, 1977 - 1979
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1974 - 1976
Johns Hopkins University School of MedicineClass of 1974

Certifications & Licensure

NY State Medical License 1975 - 2024
MD State Medical License 1974 - 1983
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
Top Doctors: New York Metro Area Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
New York Magazine: Top Doctors Castle Connolly, 2002-2008, 2010-2011
Redbook Magazine: Top Breast Cancer Doctors Castle Connolly, 2001
Join now to see all

Clinical Trials

Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer Start of enrollment: 2009 Mar 06
Completed
Phase 1, Phase 2
Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases Start of enrollment: 2011 Aug 19
Completed
Phase 1, Phase 2
Exemestane and Cyclophosphamide for Metastatic Breast Cancer Start of enrollment: 2013 Sep 01
Completed
Phase 2

Publications & Presentations

PubMed

Outcomes of Breast Cancer Patients Treated with Chemotherapy, Biologic Therapy, Endocrine Therapy, or Active Surveillance During the COVID-19 Pandemic.
Douglas K Marks, Nibash Budhathoki, John Kucharczyk, Faisal Fa'ak, Nina D'Abreo, Maryann Kwa, Magdalena Plasilova, Shubhada Dhage, Phyu Phyu Soe, Daniel Becker, Alexan...> ;The Oncologist. 2022 Mar 4
24 citations
Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer
Fernanda Musa, Bhavana Pothuri, Stephanie V. Blank, Huichung T. Ling, James L. Speyer, John P. Curtin, Leslie R. Boyd, Xiaochun Li, Judith D. Goldberg, Franco M. Muggi...> ;Gynecologic Oncology. 2017 Feb 1
7 citations
Clinical trial evidence of the antitumor activity of topical imiquimod for breast cancer skin metastases.
Adams, S., Novik, Y., Oratz, R., Axelrod, D., Speyer, J., Tiersten, A., Goldberg, J. D., Bhardwaj, N., Unutmaz, D., Demaria, S., Formenti, S.> ;Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Aug 6
37 citations
Prone Breast Intensity Modulated Radiation Therapy: 5-Year Results
Etin-Osa Osa, K. DeWyngaert, Daniel F. Roses, James L. Speyer, Amber A. Guth, Deborah Axelrod, Maria Fenton Kerimian, Judith D. Goldberg, Silvia C. Formenti> ;International Journal of Radiation Oncology, Biology, Physics. 2014 Jul 15
57 citations
Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer.
Jasmeet Chadha Singh, Yelena Novik, Stacey Stein, Matthew Volm, M Meyers, Julia Smith, Coral Omene, James L. Speyer, Robert J. Schneider, Komal Jhaveri, Silvia C. Form...> ;Breast Cancer Research. 2014 Mar 31
160 citations
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer
Sylvia Adams, Lina Kozhaya, Frank Martiniuk, Tze-Chiang Meng, Luis Chiriboga, Leonard Liebes, Tsivia Hochman, Nicholas Shuman, Deborah Axelrod, James L. Speyer, Yelena...> ;Clinical Cancer Research. 2012 Dec 15
Phase II trial of RAD001 plus carboplatin in patients with triple-negative metastatic breast cancer.
Singh JC, Stein S, Volm M, Smith JA, Novik Y, Speyer JL, Adams S, Meyers MI, Muggia F, Schneider R, Formenti S, Davis S, Choi H, Tiersten A> ;J. Clin. Oncol.. 2011-09-20
Reduction of serum VEGF and IL-6 levels in patients with metastatic breast cancer: Results of a study of PTC299, an oral inhibitor of tumor VEGF synthesis, and aromata...
Dickler MN, Schneider BP, Volm M, Speyer JL, Novik Y, Callahan LA, Darby CH, Barth J, Elfring GL, Ogden A, Tiersten A> ;J. Clin. Oncol.. 2011-05-20
A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies.
Seiden MV, Burris HA, Matulonis U, Hall JB, Armstrong DK, Speyer J, Weber JDA, Muggia F> ;Gynecol. Oncol.. 2007-03-01
Report of first-stage accrual for NCI 5886, a phase II study of erlotinib, carboplatin and paclitaxel as first-line treatment of ovarian cancer.
Blank SV, Curtin JP, Goldman NA, Runowicz CD, Speyer JL, Tiersten AD, Dancey J, Wadler S, Muggia FM> ;J. Clin. Oncol.. 2006-06-20
9 citations
Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.
Howard S. Hochster, Elizabeth R. Plimack, John Mandeli, Scott Wadler, Carolyn D. Runowicz, Gary L. Goldberg, James L. Speyer, Robert C. Wallach, Franco M. Muggia> ;Gynecologic Oncology. 2006 Feb 1
A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Müllerian malignan...
Seiden M, Burris HA, Matulonis U, Hall J, Armstrong D, Speyer J, Tillner J, Weber D, Muggia F> ;J. Clin. Oncol.. 2005-06-01
A phase I study of carboplatin plus oral topotecan in advanced malignancies.
Kim E, Hochster H, Novik Y, Chachoua A, Speyer J, Muggia F> ;J. Clin. Oncol.. 2004-07-15
10 citations
A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
Anna C. Pavlick, Catherine Chodkiewicz, Leonard Liebes, A. Hamilton, Carolyn Wasserheit, Howard S. Hochster, James L. Speyer, Zoë Phillips, Andrea Downey, Joan Sorich,...> ;Anti-Cancer Drugs. 2004 Feb 1
10 citations
Biweekly 72-Hour 9-Aminocamptothecin Infusion As Second-Line Therapy for Ovarian Carcinoma: Phase II Study of the New York Gynecologic Oncology Group and the Eastern C...
Howard S. Hochster, Elizabeth R. Plimack, Carolyn D. Runowicz, James Speyer, Robert C. Wallach, Joan Sorich, John Mandeli, Scott Wadler, John J. Wright, Franco M. Muggia> ;Journal of Clinical Oncology. 2004 Jan 1
37 citations
Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
Howard S. Hochster, Abraham Chachoua, James L. Speyer, Juliette Escalon, Anne Zeleniuch-Jacquotte, Franco M. Muggia> ;Journal of Clinical Oncology. 2003 Jul 15
26 citations
Cardiac dysfunction in the trastuzumab clinical experience.
James L. Speyer> ;Journal of Clinical Oncology. 2002 Mar 1
71 citations
Activity and Pharmacodynamics of 21-Day Topotecan Infusion in Patients With Ovarian Cancer Previously Treated With Platinum-Based Chemotherapy
H. Hochster, Scott Wadler, Carolyn D. Runowicz, Leonard Liebes, Henry Cohen, Robert Wallach, Joan Sorich, Beth Taubes, James Speyer> ;Journal of Clinical Oncology. 1999 Aug 1
36 citations
Phase I Trial of Escalating Doses of Paclitaxel Plus Doxorubicin and Dexrazoxane in Patients With Advanced Breast Cancer
Joseph A. Sparano, James L. Speyer, William J. Gradishar, Leonard Liebes, Rajeshwari Sridhara, Sandra Mendoza, D. Fry, Merrill J. Egorin> ;Journal of Clinical Oncology. 1999 Mar 1
3 citations
A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating fac...
Howard S. Hochster, James L. Speyer, John Mandeli, Carolyn D. Runowicz, Scott Wadler, Greg Berk, Robert C. Wallach, James F. Holland> ;Gynecologic Oncology. 1999 Mar 1
36 citations
Strategies for reduction of anthracycline cardiac toxicity
James L. Speyer, C Wasserheit> ;Seminars in Oncology. 1998 Oct 1
6 citations
Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignancies.
Mark A. Rosenthal, David Dennis, Leonard Liebes, Phil Furmanski, Dania Caron, Leslie Garrison, Jay Wiprovnick, Denise Peace, Ruth Oratz, James L. Speyer, Abraham Chachoua> ;Journal of Immunotherapy. 1998 Sep 1
15 citations
PSC833: initial clinical results in refractory ovarian cancer patients.
Abbie L. Fields, Hochster H, Carolyn D. Runowicz, J Speyer, G. Goldberg, C Cohen, Dottino P, Scott Wadler, Berk G, Gretz H, John F. Mandeli, Holland J, Letvak L> ;Current Opinion in Oncology. 1998 Aug 1
47 citations
Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
Howard S. Hochster, Leonard Liebes, James L. Speyer, Joan Sorich, B Taubes, Ruth Oratz, J Wernz, Abraham Chachoua, Ronald H. Blum, Anne Zeleniuch-Jacquotte> ;Clinical Cancer Research. 1997 Aug 1
414 citations
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Sandra M. Swain, Fredrick S. Whaley, Miriam C. Gerber, Steven Weisberg, Martin York, Darcy V. Spicer, Stephen E. Jones, Scott Wadler, Ajit Desai, Charles L. Vogel, Jam...> ;Journal of Clinical Oncology. 1997 Apr 1
Join now to see all